{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:01:12Z","timestamp":1791234072391,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,29]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine the proportion of emergency patients treated with immune checkpoint inhibitors (ICIs) that require critical care admission and their requirements.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Prospective case series.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Analysis of acutely unwell patients treated with ICIs attending a tertiary UK cancer hospital between May 2018 and May 2022. The primary outcome measure was the percentage of patients treated with ICI therapy requiring ICU admission. The secondary outcome measure was whether this need was driven by an immune-mediated toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighteen (1.2%) patients of the 1561 acutely admitted patients treated with ICI therapy required an admission to ICU. Ten (55.5%) patients were admitted due to an immune-mediated toxicity; four due to pneumonitis and four due to myasthenia gravis. Seven of 10 survived their ICU admission with 6 surviving at least 6-month post-ICU discharge.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Only a small minority of emergency admissions in patients treated with ICIs require admission to ICU. This series adds further evidence that patients with organ failure due to immune-mediated toxicity may achieve good outcomes from ICU admission.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/qjmed\/hcac258","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T22:09:09Z","timestamp":1668463749000},"page":"285-287","source":"Crossref","is-referenced-by-count":13,"title":["Intensive care unit requirements in patients treated with immune checkpoint inhibitors"],"prefix":"10.1093","volume":"116","author":[{"given":"Tim","family":"Cooksley","sequence":"first","affiliation":[{"name":"From the Department of Acute Medicine, Medical Oncology and Critical Care, The Christie , Wilmslow Road , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie M J","family":"Weaver","sequence":"additional","affiliation":[{"name":"From the Department of Acute Medicine, Medical Oncology and Critical Care, The Christie , Wilmslow Road , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Haji-Michael","sequence":"additional","affiliation":[{"name":"From the Department of Acute Medicine, Medical Oncology and Critical Care, The Christie , Wilmslow Road , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"2023042923362647700_hcac258-B1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"2023042923362647700_hcac258-B2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"2023042923362647700_hcac258-B3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2021.12.033","article-title":"Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities","volume":"164","author":"Nahm","year":"2022","journal-title":"Eur J Cancer"},{"key":"2023042923362647700_hcac258-B4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2023042923362647700_hcac258-B5","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"2023042923362647700_hcac258-B6","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Onc"},{"key":"2023042923362647700_hcac258-B7","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1007\/s00520-020-05727-z","article-title":"MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors","volume":"28","author":"Rapoport","year":"2020","journal-title":"Support Care Cancer"},{"key":"2023042923362647700_hcac258-B8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.annemergmed.2018.04.019","article-title":"Adverse effects of immune checkpoint therapy in cancer patients visiting the Emergency Department of a comprehensive cancer center","volume":"73","author":"El Majzoub","year":"2019","journal-title":"Ann Emerg Med"},{"key":"2023042923362647700_hcac258-B9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2020.02.025","article-title":"Emergency presentations in patients treated with immune checkpoint inhibitors","volume":"130","author":"Cooksley","year":"2020","journal-title":"Eur J Cancer"},{"key":"2023042923362647700_hcac258-B10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13613-020-00761-w","article-title":"Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit","volume":"10","author":"Joseph","year":"2020","journal-title":"Ann Intensive Care"},{"key":"2023042923362647700_hcac258-B11","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.1007\/s00520-020-05710-8","article-title":"Multinational association of supportive care in cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors","volume":"28","author":"Suarez-Almazor","year":"2020","journal-title":"Support Care Cancer"},{"key":"2023042923362647700_hcac258-B12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2023042923362647700_hcac258-B13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/qjmed\/hcy052","article-title":"Short- and long-term outcomes of patients with solid tumours following non-surgical intensive care admission","volume":"111","author":"Murphy","year":"2018","journal-title":"QJM"}],"container-title":["QJM: An International Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/qjmed\/advance-article-pdf\/doi\/10.1093\/qjmed\/hcac258\/47256361\/hcac258.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/116\/4\/285\/50148006\/hcac258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/116\/4\/285\/50148006\/hcac258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T23:36:46Z","timestamp":1682811406000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/qjmed\/article\/116\/4\/285\/6827803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,11,15]]},"published-print":{"date-parts":[[2023,4,29]]}},"URL":"https:\/\/doi.org\/10.1093\/qjmed\/hcac258","relation":{},"ISSN":["1460-2725","1460-2393"],"issn-type":[{"value":"1460-2725","type":"print"},{"value":"1460-2393","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,11,15]]}}}